Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advance

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results

and Business Highlights

August 5, 2025, Fort Lee, NJ - Nuvectis Pharma,

Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development

of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial

results for the second quarter 2025 and provided an update on recent business progress.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented,

"In the second quarter and subsequent weeks we have had a series of important events that we believe put the company in an excellent

position for growth." Mr. Bentsur continued, "We announced the successful completions of the NXP900 Phase 1a dose escalation

study in patients with advanced solid tumors and of the NXP900 drug-drug interaction study in healthy volunteers, both strongly supporting

the initiation of the NXP900 Phase 1b program, expected to start imminently. As for NXP800, over the next few months, we plan to explore

potential opportunities of NXP800 in cancer types such as endometrial and prostate." Mr. Bentsur added, "On the financial side,

in July we strengthened our cash position following the acquisition of shares by a healthcare specialized institutional investor through

our ATM facility, bringing our second quarter end proforma cash to approximately $39 million, which we expect can fund our operations

into 2H 2027." Mr. Bentsur concluded, "The last few months have been very significant for Nuvectis, and we believe that we

are well positioned to deliver on our ambitious plan for NXP900."

Second Quarter 2025 Financial Results

Cash and cash equivalents were $26.8 million as of June 30, 2025, compared

to $18.5 million as of December 31, 2024. The increase of $8.3 million in the cash balance as of the end of the second quarter of 2025

is a result primarily of our public offering in February 2025, partially offset by the operating expenses for the first half of 2025.

The Company's net loss was $6.3 million for the three months ended

June 30, 2025, compared to $4.4 million for the three months ended June 30, 2024, an increase in net loss of $1.9 million.

The increase in net loss in the second quarter of 2025 was primarily

due to the NXP900 DDI study, which has been completed. The three months ended June 30, 2025, also includes $1.8 million of non-cash stock-based

Research and development expenses, including non-cash stock-based compensation,

were $3.6 million for the three months ended June 30, 2025, compared to $2.9 million for the three months ended June, 30, 2024, an increase

General and administrative expenses, including non-cash stock-based

compensation, were $3.0 million for the three months ended June 30, 2025, compared to $1.7 million for the three months ended June 30

2024, an increase of $1.3 million.

Interest income was $0.2 million for the three months ended June 30,

2025, compared to $0.2 million for the three months ended June 30, 2024.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the

development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's

assets include two clinical-stage drug candidates, NXP900 and NXP800. NXP900 is an oral small molecule inhibitor of the SRC Family of

Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions

of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed Phase 1a dose escalation and is progressing

toward Phase 1b. NXP800 is an oral small molecule GCN2 activator that has demonstrated anti-tumor activity in recurrent, platinum-resistant,

ARID1a-mutated ovarian cancer, and may be explored in the future in other cancer types. For additional information about Nuvectis Pharma

please visit: https://nuvectis.com/

Forward Looking Statements

This press release contains "forward-looking

statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties,

including statements regarding the expected and intended use of proceeds from the offering. All statements, other than statements of historical

fact, contained in this press release are forward-looking statements, including statements regarding the intended. Forward-looking statements

contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"

"could," "estimate," "expect," "intend," "seek," "may," "might,"

"plan," "potential," "predict," "project," "target," "aim," "should,"

"will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements

contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, including estimates and projections

about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business

strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties,

risks, assumptions, market and other conditions, and other factors that are difficult to predict and include statements regarding the

preclinical studies for NXP900 and statements regarding NXP900's therapeutic potential and the expected timing for the start of and expectations

for the NXP900 Phase 1b program. Further, certain forward-looking statements are based on assumptions as to future events that may not

prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the

section titled "Risk Factors" in our Form 10-Q for the quarter ended March 31, 2025 and our other public filings with the Securities

and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to

time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements

contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only

as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions

to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances

on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking

statements contained in the Private Securities Litigation Reform Act of 1995.

Chairman, Chief Executive Officer and President

Media Relations Contact:

NUVECTIS PHARMA, INC.

(USD in thousands, except per share and share

* Represents an amount lower

NUVECTIS PHARMA, INC.

STATEMENT OF OPERATIONS

(USD in thousands, except per share and share